$ICHR

MacKenzie Iain sold $653K of ICHR

MacKenzie Iain sold 9,933 shares of ICHOR HOLDINGS, LTD. (ICHR) at an average of $65.76 ($65.19–$68.14, $0.65M total) across 4 trades on 2026-08-18 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · MacKenzie Iain
Published Aug 20, 2026, 9:27 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 20, 2026, 9:32 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$ICHR
Bearish
medium confidence
Mentioned
$ICHR
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ICHRBearishLow
01

Why it matters

The disclosed sale adds a data point for short‑term sentiment but is unlikely to drive significant price movement.

02

Market read

Primary insider sale filing; modest relevance for traders monitoring ICHOR.

03

What to watch

The director retained 122,427 shares, indicating continued confidence in the company.

Relevance 4/10Novelty 4/10Timing: filed today

Background

SEC Form 4 filings disclose insider transactions. This filing reports a director's open‑market sale under a 10b5‑1 plan.

Company-level read

Ticker impact

$ICHRBearishMedium confidence
Context

Director MacKenzie Iain sold 9,933 shares for $653,176 on 2026-08-18 via a 10b5‑1 plan.

Expected impact

Potential short‑term dip of 1‑2% as the market digests the sale.

Evidence & confidence

A $653k sale by a director is a primary Form 4 disclosure but the amount is modest for a listed biotech, limiting material impact.

Market effects

Minimal effect on the broader biotech sector; insider sales are common and rarely shift sector sentiment.

No notable regional impact; the filing is specific to ICHOR.

Limited global relevance; only relevant to investors tracking ICHOR.

Counterpoint

The sale could be a routine liquidity move under a pre‑arranged plan, not a bearish signal.

Key entities

  • MacKenzie Iain

    Director of ICHOR Holdings who executed the sale.

  • ICHR

    ICHOR Holdings, Ltd., a biotech listed on NASDAQ.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ICHRMedAI 8/10

Ichor Holdings, Ltd. Q2 2026 Earnings Call Summary

Ichor Holdings reported Q2 2026 revenue up 15% sequentially, with gross margin rising 130 bps to 14.1%. Management attributed a Q2 revenue shortfall to brief flow-control part shortages resolved after quarter end, shifting volume to Q3. It expects sequential revenue growth above 10% for the next two quarters and full-year 2026 revenue up at least 30% vs 2025, with gross margin gains of 100 bps per quarter. An ATM raised $195m net proceeds.

$ICHRMed

Why is Ichor Holdings stock sliding today?

Ichor Holdings (ICHR) shares fell 12.9% in after-hours after its Q2 2026 results. The company reported adjusted EPS of $0.34 on revenue of $294.8M, beating consensus, with gross margin at 14.1%. Operating cash flow was -$15.9M and it completed a $200M at-the-market offering. Q3 revenue guidance was $315M-$345M.

$PLTRMed

After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR

Investing.com’s after-hours movers report highlights Palantir (PLTR) up 10% after Q2 EPS of $0.41 and $1.94B revenue, with 2026 revenue guidance raised to $8.15–$8.158B. Snap (SNAP) rose 9.6% on Q2 revenue $1.6B and Q3 guidance $1.7–$1.74B. Backblaze (BLZE) gained 16% on Q2 beat and raised 2026 revenue to $172–$174M. ON (ON) +5%, ICHR -11%, WGS -7%, WHR -4%.

$ICHRMedAI 9/10

Ichor Holdings, Ltd. $ICHR Shares Bought by Royce & Associates LP

Royce & Associates LP increased its Ichor Holdings (NASDAQ:ICHR) stake by 48.5% in Q4 to 1,449,082 shares, worth $26.71M, after buying 473,440 shares, according to SEC filings cited by HoldingsChannel. Other institutions also added shares. CEO Philip Ryan Sr. Barros sold 21,000 shares at $46.63. Analysts raised price targets; consensus average is $64.57.